ABSTRACT. The aim of this collaborative study was to normalized by therapy, the levels of the catabolites of investigate whether guanidino compound analyses in the arginine are still elevated. (Pediatr Res 27: 297-303,1990) biologic fluids can be used as a complementary diagnostic parameter for hyperargininemia. Guanidino compounds were determined in the biologic fluids of all known living hyperargininemic patients using a cation exchange chromatographic system with a fluorescence detection method. The serum arginine, homoarginine, a-keto-6-guanidinoDeficiency of arginase, the last enzyme of the urea cycle, leads valeric acid, argininic acid, and N-a-acetylarginine levels to hyperargininemia. The first clinical and biochemical descripof all the hyperargininemic patients are higher than the tions of two sisters affected with hyperargininemia were pubnormal range. Similar increases were seen for the urinary lished in 1969 (1) and 1970 (2, 3). Five y later, another sister was excretion of a-keto-6-guanidinovaleric acid and argininic diagnosed shortly after birth (4). Since then, 19 other cases from acid. Untreated hyperargininemic patients have the highest 17 families have been reported (5-22). Patients with hyperargiguanidino compound levels in cerebrospinal fluid. How-ninemia present a neuropsychiatric syndrome consisting of varyever, even under therapy, the arginine, homoarginine, a-ing degrees of mental retardation, epilepsy, and progressive spasketo-6-guanidinovaleric acid, and argininic acid levels in ticity. This latter symptom is at variance with other defects of cerebrospinal fluid are still increased. Protein restriction the urea cycle. Some patients have, in addition, recurrent epialone is not sufficient to normalize the hyperargininemia, sodes of vomiting and irritability accompanied by moderate but protein restriction together with supplementation of hyperammonemia. As a consequence of the arginase deficiency, essential amino acids with or without sodium benzoate the patients accumulate excessive arginine. Some secondary cadecreases further the arginine levels. However, whereas tabolites of arginine, guanidino compounds, are massively exthe argininemia can be normalized, the catabolites of ar-creted in the urine of these patients (23). Figure 1 shows some ginine are still increased. We conclude that the urinary proposed catabolic pathways of arginine in patients with hyperamino acid levels may remain normal in hyperargininemia, argininemia. whereas consistent increases of the guanidino compounds In hyperargininemia it is unclear whether ammonia is the are observed. Thus, guanidino compound analyses can be principal toxin. Indeed, the presence of normal or only slightly used as a complementary biochemical diagnostic parameter elevated ammonia levels has been demonstrated in several pafor hyperargininemia. Although the argininemia can be tients (6, 7, 9, 15) , and the progressive spasticity typically en-
restriction was also the first approach to therapy of hyperargini- thesis pathway, has also been found to be beneficial in ammonia detoxification (27) . Lambert et al. (28) demonstrated an arrest in the developing spasticity and an increase of mental acuity in one patient subjected to such treatment. We started this collaborative study to investigate whether the guanidino compounds can furnish complementary diagnostic parameters for hyperargininemia that can remain undiagnosed by urinary amino acid analysis only (5) . We present the followup of the serum guanidino compound levels during 8 y of therapy in a hyperargininemic patient.
MATERIALS AND METHODS
Patients. Twenty-two cases have been published. The patients described by Jorda et al. (19) , Endres et al. (16) , and Sakiyama et al. (12) have died. No biologic fluids from these patients were available for this study. The patient of Antonozzi and coworkers (20, 21) , from which plasma and urine were included in this study, died a few weeks after sampling, as a consequence of an acute febrile illness with status epilepticus. Samples were collected from each of the living, published cases. Their clinical and biochemical descriptions have been reported earlier (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . Eight unpublished cases were included as well: two cases of Dr. I. A. Qureshi (Montreal), two cases of Dr. C. Bachmann (Lausanne) and Dr. Colombo (Bern), one case of Dr. I. Rezvani and Dr. M. Batshaw (Philadelphia); one case of Dr. Edwards (Birmingham), one case of Dr. N. Chamoles (Buenos Aires), and one case of Dr. R. Gatti (Genova). We were unable to collect both serum and urine as well as cerebrospinal fluid from each patient. In this study 25 urine, 19 serum, and seven cerebrospinal fluid samples of different hyperargininemic patients were collected. For the purposes of the study, one would ideally consider samples of untreated patients. However, it is medically and ethically unacceptable to interrupt the therapies. Therefore, samples of patients under no treatment (n = 2), protein restriction (n = lo), or combined therapy of protein restriction with supplementation of essential amino acids with (n = 8) or without (n = 6) sodium benzoate were included in this study. Doses of the commercial arginine-free essential amino acid mixtures, ranging from 0.4-0.7 g/kg/d, were given to the patients. When sodium benzoate was administered, doses of 250 mg/kg/d were given. One patient was on a protein restricted diet together with essential amino acids and a supplementation of ornithine (100 mg/kg/d) and lysine (250 mg/kg/d) (14) . From the 26 hyperargininemic patients two were younger than 2 y and one was an adult at the time of sampling. The others were children (n = 15, 2 y to puberty) and adolescents (n = 8, puberty to 18 y).
The patients were only included after informed consent was obtained in accordance with the principles of the declaration of Helsinki.
Controls. The age-matched control group for serum and urinary values consisted of healthy volunteers and patients admitted to the hospital for minor surgery and were without history of neurologic, metabolic, or renal disease. Sampling was done before surgery after overnight fasting. The control group for normal cerebrospinal fluid levels was comprised of patients presenting with neurologic complaints in whom, however, after performing a series of clinical and neurochemical diagnostic tests, no neurologic, metabolic, or renal disease was diagnosed.
Collection and preparation of samples. Sampling was done in the morning. The procedure for collection and preparation of serum and cerebrospinal fluid samples has been reported (29) . Equal volumes of a 200 g/L trichloroacetic acid solution were mixed with urine and centrifuged in a Beckman microfuge (Beckman Instruments Inc., Fullerton, CA). Clear supernatant was diluted and used for guanidino compound analysis.
Laboratory methods. The concentration of the guanidino compounds was determined using a Biotronic LC 6001 amino acid analyzer (Biotronic GmbH, Maintal, FRG) adapted for guanidin0 compound determination. The guanidino compounds were separated over a cation exchange column using sodium citrate buffers and were detected with the fluorescence ninhydrin A and B, serum guanidino compound levels (yM). Shaded areas, range of normal values. ARG, arginine; HARG, homoarginine; a-K-6-GVA, a-Keto-6-guanidino-valeric acid; ARGA, argininic acid; N-a-AA, N-a-acetylarginine; GAA, guanidinoacetic acid; y-GBA, y-guanidinobutyric acid; GSA, guanidinosuccinic acid. Free diet ( n = 1) 0.; protein restriction ( n = 6) 0; protein restriction + essential amino acids ( n = 4) A; protein restriction + essential amino acids + sodium benzoate ( n = 7) A; protein restriction + essential amino acids + Orn and Lys ( n = 1) *. Eleven of 18 hyperargininemic patients have y-guanidinobutyric acid levels below detection limit and all but three have guanidinosuccinic acid levels lower than the detection limit.
N-a-AA GAA y -G B A G S A Fig. 3 . A and B, urinary guanidino compound levels (ymol/g creatinine). Shaded areas = range of normal values. For abbreviations see Figure 2 . Free diet ( n = 2) 0; protein restricion (n = 10) 0; protein restriction + essential amino acids ( n = 5) A; protein restriction + essential amino acids + sodium benzoate ( n = 7) A; protein restriction + essential amino acids + Orn and Lys ( n = 1) *. Four patients under a combined therapy of protein restriction together with essential amino acids excreted guanidinosuccinic acid and homoarginine levels lower than the detection limit.
method (30, 31) . Table 1 lists the 13 guanidino compounds determined and their normal levels in serum, urine, and cerebrospinal fluid. It was our purpose to study the guanidino compound levels as a complementary diagnostic parameter for hyperargininemia, and we present in the figures the range values of all the studied controls.
RESULTS
Guanidino compounds in serum, urine, and cerebrospinaifluid. From the 13 guanidino com~ounds ~uantitated in serum of hyperarginine&ic patients, the levels of P-guanidinopropionic acid, guanidine, and methylguanidine were below the detection 
* For abbreviations of guanidino compounds see Figure 2 .
7 Four of the five patients under a combined therapy of protein restriction together with essential amino acids excreted GSA and HArg levels lower than the detection limit. However, to be able to do statistic evaluations we used a value of 0.20 Krnol/g creatinine for GSA and 1 Kmol/g creatinine for HArg. These values are half that of the lowest excreted GSA and HArg levels in urine of all the hyperargininemic patients in this study. $ Significantly different from the group of untreated and protein restricted (FD + PR) patients ( p < 0.01).
5 Significantly different from the group of untreated and protein restricted (FD + PR) patients (p < 0.05).
limit in all patients and comparable to controls. The serum levels of creatine and creatinine were within the normal range for all the hyperargininemic patients. Therefore these five guanidino compounds are not included in Figure 2 . The serum arginine, homoarginine, a-keto-6-guanidinovaleric acid, argininic acid, and N-a-acetylarginine levels of all the hyperargininemic patients were higher than the normal range. The serum guanidinoacetic acid levels of some hyperargininemic patients fell within the normal range. The y-guanidinobutyric acid levels of most of the studied hyperargininemic patients were comparable to controls. However, the serum guanidinosuccinic acid levels of most of the hyperargininemic patients were below control. The considerable patient-to-patient variations in the levels of the serum guanidino compounds are probably a consequence of the therapy. Proving this by statistical analysis is dificult because of a wide range of the individual values in each group. However, we have attempted to make this comparison in Table 2 by using nonparametric methods (Mann-Whitney test). For the purpose of this comparison, the untreated and protein-restricted hyperargininemic patients have been considered as one group because hyperargininemic patients, as with the other urea cycle patients, mostly impose upon themselves a restricted protein diet. Untreated and protein-restricted hyperargininemic patients had mostly higher serum arginine, a-keto-6-guanidinovaleric acid, argininic acid, and N-a-acetylarginine levels than those under a combined therapy of protein restriction together with a supplementation of essential amino acids with or without sodium benzoate. The serum homoarginine levels of the hyperargininemic patients under a combined therapy had a tendency to be higher than those of the untreated and protein-restricted patients. This is probably in relation with the fact that the essential amino acid supplementation contains lysine, a metabolic precursor of homoarginine (32, 33). The patient-to-patient variations in the levels of y-guanidinobutyric acid and guanidinosuccinic acid are difficult to interpret because most were under the detection limit. The urinary excretion of guanidine, methylguanidine, and creatine were within the normal range for all the studied hyperargininemic patients. The excretion of P-guanidinopropionic acid from most of the 25 patients was also comparable to controls, but eight were abnormal: seven had excretion about four times and one about 15 times higher than the upper limit of the controls. These four guanidino compounds are not included in Figure 3 . The urinary excretion of a-keto-6-guanidinovaleric acid and argininic acid of all the studied hyperargininemic patients were higher than the normal range. The urinary excretion of Na-acetylarginine and y-guanidinobutyric acid of most of the patients were higher than normal, but the majority had arginine, homoarginine, and guanidinoacetic acid excretion within the normal range. As for the serum values, the urinary excretion of guanidinosuccinic acid of all the studied hyperargininemic patients were lower than the control levels. The considerable patient-to-patient variations in the urinary excretion of the guanidino compounds are probably, as in serum, also a consequence of the therapy. Statistical analyses are again difficult because of the wide range of the individual values in each group.However, we have attempted to make this comparison in Table 3 by using again the Mann-Whitney test. The untreated and protein-restricted hyperargininemic patients have been put in the same group; they had higher urinary excretion of arginine, homoarginine, a-keto-6-guanidinovaleric acid, argininic acid, N-a-acetylarginine, guanidinoacetic acid, and guanidinosuccinic acid compared to patients under a combined therapy of protein restriction with a supplementation of essential amino acids, with or without sodium benzoate.
The cerebrospinal fluid levels of creatine, guanidinoacetic acid, P-guanidinopropionic acid, creatinine, y-guanidinobutyric acid, guanidine, and methylguanidine of all the patients were within the normal range, except for the untreated hyperargininemic patient, who had y-guanidinobutyric acid and guanidine levels about 10 times higher than the upper limit of controls (data not shown). The untreated hyperargininemic patient had the highest levels of arginine, a-keto-6-guanidinovaleric acid, argininic acid, N-a-acetylarginine (Fig. 4) . However, the homoarginine level in cerebrospinal fluid of the untreated patient was the lowest. The tendency to higher cerebrospinal fluid homoarginine levels in hyperargininemic patients receiving an essential amino acid mixture could be related to lysine, which can be a metabolic precursor of homoarginine. Figure 4 also shows that even under therapy, the arginine, homoarginine, a-keto-6-guanidinovaleric acid, and argininic acid levels in cerebrospinal fluid of hyperargininemic patients are still higher than in controls.
Serum guanidino compound levels during therapy. Figure 5 shows the follow-up of the serum guanidino compound levels during 8 y of therapy in one hyperargininemic patient. Only through restriction of the daily arginine intake (protein restriction and supplementation of essential amino acids without arginine) the serum arginine levels could be lowered to the upper limit of the control range. During the first years (1982-1984) of a combined therapy of protein restriction together with a supplementation of essential amino acids with sodium benzoate, the serum guanidinoacetic acid and N-a-acetylarginine levels were brought into the upper control levels. However, a longer follow-up shows that these guanidino compound levels could not be normalized. The decrease and the normalization of the serum arginine levels could certainly not normalize the serum a-keto-a-guanidinov-ARG HARG a-K-6-GVA ARGA N-a-AA GSA aleric acid, argininic acid, and homoarginine levels, which remained considerably increased.
DISCUSSION
Quantitative determination of guanidino compounds in the biologic fluids of hyperargininemic patients shows that some guanidino compounds are greatly increased. As a consequence of the arginase deficiency the serum arginine and homoarginine levels are increased. Taking into account the upper control limits (Table I) , it seems that the secondary catabolic pathway that is most activated in hyperargininemic patients is the one with the formation of a-keto-6-guanidinovaleric acid. The increase in serum is about 100-fold. This formation is probably catalyzed by a transaminase. The increased activity of the hydrogenation of a-keto-6-guanidinovaleric to argininic acid is also remarkable. The increase of the transamidination activity involved in the biosynthesis of guanidinoacetic acid, y-guanidinobutyric acid, and ,f3-guanidinopropionic acid in hyperargininernic patients is less pronounced. It must also be stressed that the transamidination of arginine with y-guanidinobutyric acid formation can always be overestimated in hyperargininemic patients. Indeed, a-keto-6-guanidinovaleric acid is an unstable product and degrades partially to y-guanidinobutyric acid by chemical oxidation (34) . Therefore the time between sampling and analysis must be as short as possible to prevent overestimation of the y-guanidinobutyric acid and an underestimation of the a-keto-d-guanidinovaleric acid levels.
The biosynthesis of guanidinosuccinic acid is related to urea (35). This is reflected in the Figures 2B, 3B , and 4: untreated and protein-restricted hyperargininemic patients probably have higher guanidinosuccinic acid levels in their biologic fluids than those under a combined therapy of protein restriction together with essential amino acid supplementation with or without sodium benzoate. Hyperargininemic patients have a decreased urea cycle activity. Protein restriction and supplementation of essential amino acids further decrease the urea cycle activity. The urea biosynthesis is also decreased by administration of sodium benzoate.
The abnormal catabolism of arginine leads to an accumulation of some secondary catabolites in serum as well as in cerebrospinal fluid. The results of Figure 2A and B and Figure 3 A and B demonstrate that the quantitative determination of the guanidino compounds has complementary diagnostic implications in hyperargininemia. Early diagnosis is very important to prevent neurologic complications (8) . At present hyperargininemia is biochemically diagnosed by increased arginine levels in serum. The diagnosis can be confirmed by measuring the arginase activity in erythrocytes. Determination of arginine in urine alone can yield a false-negative diagnosis. Indeed, some untreated hyperargininemic patients have urinary arginine excretion levels around the upper normal levels, whereas serum arginine levels are increased. These patients also do not show a secondary lysinecystinuria pattern seen in others. They can remain undiagnosed by urinary amino acid analysis only (5) . Even if a lysine-cystinuria pattern is seen, the diagnosis must be confirmed by serum arginine determinations. However, in urine of hyperargininernic patients with normal urinary arginine levels, the excretion levels of a-keto-6-guanidinovaleric acid and argininic acid are clearly increased. It must be stressed again that in this collaborative study more than half of the hyperargininemic patients were under a combined therapy of protein restriction together with essential amino acid supplementation with or without sodium benzoate. Still higher guanidino compound levels are to be expected in the biologic fluids of untreated patients.
The interpatient study as well as the intrapatient study presented in this report suggest that protein restriction alone is not sufficient to normalize the hyperargininemia. Only a combined therapy of protein restriction together with a supplementation of essential amino acids with or without sodium benzoate seems to be eficacious in further decreasing the arginine levels in the biologic fluids. However, it must be stressed that when the argininemia could be normalized, these arginine levels in serum are still too high for hyperargininemic patients with an abnormal arginase activity, which results in still abnormal levels of the catabolites of arginine. If it is proven that the accumulated guanidino compounds have an influence or are partially responsible for some neurologic symptoms seen in hyperargininemic patients, then dietary and medical treatment should also focus on efforts to decrease the guanidino compound levels other than arginine. Prevention and/or decrease of neurologic complications obtained by institution of a protein restriction together with a supplementation of essential amino acids with or without sodium benzoate (6, 8, 28) , coincided with a substantial lowering of the guanidino compounds and further support the hypothesis that guanidino compounds are neurotoxins in hyperargininemia. Therefore, it seems indicated also to perform guanidino compound determinations for each patient, especially with each change in therapeutic regimen, in an attempt to lower these toxins as much as possible.
